# IXO (Irinotecan, Xeloda, Oxaliplatin) in Rectal Cancer

> **NCT01237665** · PHASE2 · UNKNOWN · sponsor: **Ottawa Hospital Research Institute** · enrollment: 15 (estimated)

## Conditions studied

- Rectal Cancer

## Interventions

- **DRUG:** IXO regimen

## Key facts

- **NCT ID:** NCT01237665
- **Lead sponsor:** Ottawa Hospital Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2010-09
- **Primary completion:** 2012-12
- **Final completion:** 2017-12
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2012-10-15

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01237665

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01237665, "IXO (Irinotecan, Xeloda, Oxaliplatin) in Rectal Cancer". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT01237665. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*